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olaparib as radiosensitizer to efficacy of olaparib as single 
agent in cell systems with different genetic backgrounds. 
Materials and Methods: Mouse mammary tumor cell line with 
BRCA2 deficiency, its isogenic control cell line with restored 
BRCA2 function and a panel of human head and neck 
squamous cell carcinoma (HNSCC) cell lines were treated 
with different doses of olaparib and radiation. Survival was 
quantified using proliferation and clonogenic assays. To 
assess the effect of olaparib and radiation on PARP activity, 
we measured PAR levels using an ELISA-based immunoassay. 
Results: As reported previously, olaparib alone has efficacy 
at significantly lower concentrations in BRCA2-deficient cells 
than in BRCA2-proficient cells. Efficacy of olaparib alone 
differed among the human HNSCC cells. 
Olaparib radiosensitized all tested cell lines, however, to a 
different extent and at different dose ranges. Importantly, in 
all but one HNSCC cell line that is hypersensitive to olaparib 
alone, effective radiosensitization always established at ten-
fold lower concentrations than single agent activity.  
Radiation increased PAR levels in both BRCA2-deficient and 
BRCA2-proficient cells. Olaparib reduced PAR levels in a 
dose-dependent fashion and to a similar extent in BRCA2-
deficient and BRCA2-proficient cells. Low doses of olaparib 
that result in effective radiosensitization without 
concomitant single agent activity fully abolished PAR 
induction by radiation, without fully abolishing baseline PAR 
levels.  
Conclusions: Our results show that olaparib acts as an 
effective radiosensitizer at significantly lower doses than 
those required for single agent activity. We conclude that 
olaparib-induced radiosensitization occurs by the prevention 
of PAR induction upon radiation, rather than by full PARP 
inhibition as proposed to be required for single agent 
activity. From these data we would predict that 
radiosensitization may be present at low olaparib dose levels 
in the clinic. This study emphasizes the importance to 
evaluate the concept of biological optimal dosing in novel 
radiation-targeted agent combinations. 
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Purpose/Objective: In recent years there has been 
considerable interest on the use of gold nanoparticles (GNPs) 
combined with radiotherapy to improve tumor control. 
Radiosensitization in cancerous cells in presence of GNP has 
been demonstrated both in vitro and in vivo at kilo- and 
mega- voltage energies [1,2,3,4]. GNPs exhibit unique 
physical and chemical properties, and can be designed to 
interact with various biomolecules, resulting in improved 
diagnosis and treatments efficacy when bound to molecules 
that target specific cell receptors. A quantification of the 
expected clinical improvements is however still lacking. In 
this work a new approach for estimating the improved 
nanoparticle-driven radiosensitivity is presented and a 
quantification of the treatment optimality as a function of 
GNP uptake is performed. 
Materials and Methods: In order to assess the biological 
effects, a stochastic radiobiological model derived from the 
Local Effect Model (LEM) [5,6] approach was coupled with 
Monte Carlo simulations performed using Geant4 toolkit, so 
as to estimate the local dose deposited from secondary 
electrons at the nanometric level. A closed analytical 
formulation of the model was also derived for MV irradiation. 
The model was benchmarked for MDA-MB-231 breast cancer 
cells with varying gold concentration and then used to 
investigate breast cancer cases for planned treatments with 
both 6 MV and 15 MV photons. Treatment simulations of 6 
patients were performed for each energy, in which a 
parametrization of the GNPs uptake with varying tumor 
selectivity was introduced. The expected treatment 
optimality as a function of the spatially varying gold uptake 
was quantified in terms of Tumor Control Probability (TCP) 
and Normal Tissue Complication Probability (NTCP). 
Results: Results show good agreement between simulations 
and experimental clonogenic survival assays for both 6 MV 
and 15 MV, suggesting that the models could be used to 
estimate the experimental outcomes in a clinical setup. The 
breast cancer treatment simulations show improved tumor 
control when GNPs bound to targeting agents are present. 
For both treatments with 3 Gy per fraction and 13 fractions 
(START A) and 2.67 Gy with 15 fractions (START B) [8], a 
maximum TCP increase of 20% was observed in the 6 MV case, 
assuming a maximum concentration of 12 uM GNP in the 
tumoral region. 
Conclusions: A model to account GNP uptake and tissue 
radiosentitization was implemented and included in the 
simulation of breast cancer treatments. In addition to the 
improved treatment efficacy, the possibility of a short course 
of fractionation in combination with GNP was also quantified. 
1 Hainfeld, JF et al. (2004) Phys Med Biol 49 
2 Kong, T et al. (2008) Small 4 
3 Rahman, WN et al. (2009) Nanomedicine: NBM 5 
4 Jain S et al. (2012) Br J Radiol 85 
5 Scholz M & Kraft G (1994) Radiat Prot Dosim 52 
6 McMahon S et al. (2011) Sci Rep 1 
7 Jain S et al. (2011) Int J Radiat Oncol 79 
8 Haviland JS et al. (2013) Lancet Oncol 14  
   
OC-0619   
Targeting HSP90 with the small-molecule inhibitor NW457 
sensitizes human glioblastoma cells to ionizing radiation 
V. Albrecht1, M. Orth1, L. Kinzel1, K. Seidl1, N. Winssinger2, A. 
Friedl1, C. Belka1, K. Lauber1 
1Ludwig-Maximilians-University, Department of Radiation 
Oncology, Muenchen, Germany  
2University of Geneva, Department of Organic Chemistry, 
Muenchen, Germany  
 
Purpose/Objective: A common characteristic of glioblastoma 
multiforme is radioresistance. Hence, novel treatment 
concepts involve the application of molecularly targeted 
agents that interfere with pathways mediating glioma cell 
radioresistance and invasiveness. One molecule contributing 
to glioblastoma cell growth and survival is the heat shock 
protein 90 (HSP90), a chaperone that regulates the proper 
folding and stability of numerous client proteins which are 
involved in promoting tumorigenesis, proliferation, invasion, 
and survival.  
The novel pochoxime-based HSP90 inhibitor NW457 binds to 
the N-terminal ATP binding site of HSP90, thus leading to the 
destabilization and proteasomal degradation of crucial client 
proteins. Here, we report on the mechanisms involved in 
NW457-mediated radiosensitization of human glioblastoma 
cell lines as well as on the impact of NW457 on the migratory 
phenotype.  
Materials and Methods: DNA damage response regulators 
were analyzed by qPCR. Treatment response of LN229 and 
T98G to ionizing radiation in the presence or absence of 
